CD19 and B-cell non-Hodgkin lymphoma: Through this study, we conclude that the outcome for B‐cell lymphoma patients following CD19 targeted CAR‐T therapy when facing omicron infection was improved over time, but aggressive precautionary measures were particularly crucial for patients with high risk factors, such as the prevention of tixagevimab and cilgavimab, although currently not yet available in China.31